SpringWorks Therapeutics Slide Continues

SpringWorks Therapeutics, Inc. (SWTX) shares are sliding more than 49 percent, continuing a decline over the last several days. The company announced initial clinical data from the Phase 1/2 study evaluating nirogacestat, in combination with BLENREP or belantamab mafodotin-blmf, GSK plc's (GSK) antibody drug conjugate targeting B-cell maturation agent in patients with relapsed or refractory multiple myeloma.

Currently, shares are at $14.29, down 53.65 percent from the previous close of $30.83 on a volume of $2,668,050. For the 52-week period, the shares have traded in a range of $13.60-$89.75 on average volume of 599,100.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Follow RTT